A (not so) dangerous method: pXRF vs. EPMA-WDS analyses of copper-based artefacts

Analysis of metal objects with portable and handheld X-ray fluorescence spectrometry has become increasingly popular in recent years. Here, methodological concerns that apply to non-destructive, surface examination with XRF instruments of ancient metal artefacts are discussed based on the comparative analyses of a set of copper-based objects by means of portable X-ray fluorescence (pXRF) and electron probe microanalyser (EPMA). The analytical investigation aims to explore issues of instrument comparability and reliability of the non-invasive pXRF results. The different analytical approaches produce a comparable pattern for the major element concentrations, but substantial variation is evident when it comes to the absolute values for major and minor/trace elements

Forging a New World Order? Interdisciplinary Perspectives on the Management of Metalworking and Ideological Change in the Late Bronze Age Carpathian Basin

The Carpathian Basin was a highly influential centre of metalworking in the 2nd mil. BC. Nevertheless, despite the abundance of metal objects from the Late Bronze Age, the scarcity of contextually associated metalworking remains representing distinct phases of the metalworking cycle from this region is striking. Here, we explore Late Bronze Age metalworking through the lens of a uniquely complete metalworking assemblage from the site of Șagu from contexts spanning the sixteenth to early thirteenth century BC. This material provides insights into changes in craft organisation following socio-political change after the collapse of Middle Bronze Age tell-centred communities. Our approach combines analytical and experimental data together with contextual analysis of technical ceramics (crucible, mould, and furnace fragments) to reconstruct the metalworking chaîne opératoire and place Șagu in its broader cultural context. Analyses demonstrate clear technological choices in ceramic paste recipes and strong interlinkages between metallurgy and other crafts practised on site, from domestic pottery production to building structures. Experimental replications reveal important intrinsic and experiential aspects of metallurgical activities at Șagu. Evidence on the spatial organisation of metallurgical workflows (routine sequence of actions and decisions) suggests they incorporated a high degree of visibility, which marks a distinct change in the use of craft space compared to the context of densely occupied Middle Bronze Age tells nearby. Combined, our archaeometric, experimental, and contextual results illustrate how changes in metalworking activities in the Late Bronze Age Carpathian Basin were deeply embedded in an ideological shift in the aftermath of the breakdown of Middle Bronze Age tells and the emergence of new social structures

Impact of safety-related dose reductions or discontinuations on sustained virologic response in HCV-infected patients: Results from the GUARD-C Cohort

BACKGROUND: Despite the introduction of direct-acting antiviral agents for chronic hepatitis C virus (HCV) infection, peginterferon alfa/ribavirin remains relevant in many resource-constrained settings. The non-randomized GUARD-C cohort investigated baseline predictors of safety-related dose reductions or discontinuations (sr-RD) and their impact on sustained virologic response (SVR) in patients receiving peginterferon alfa/ribavirin in routine practice. METHODS: A total of 3181 HCV-mono-infected treatment-naive patients were assigned to 24 or 48 weeks of peginterferon alfa/ribavirin by their physician. Patients were categorized by time-to-first sr-RD (Week 4/12). Detailed analyses of the impact of sr-RD on SVR24 (HCV RNA <50 IU/mL) were conducted in 951 Caucasian, noncirrhotic genotype (G)1 patients assigned to peginterferon alfa-2a/ribavirin for 48 weeks. The probability of SVR24 was identified by a baseline scoring system (range: 0-9 points) on which scores of 5 to 9 and <5 represent high and low probability of SVR24, respectively. RESULTS: SVR24 rates were 46.1% (754/1634), 77.1% (279/362), 68.0% (514/756), and 51.3% (203/396), respectively, in G1, 2, 3, and 4 patients. Overall, 16.9% and 21.8% patients experienced 651 sr-RD for peginterferon alfa and ribavirin, respectively. Among Caucasian noncirrhotic G1 patients: female sex, lower body mass index, pre-existing cardiovascular/pulmonary disease, and low hematological indices were prognostic factors of sr-RD; SVR24 was lower in patients with 651 vs. no sr-RD by Week 4 (37.9% vs. 54.4%; P = 0.0046) and Week 12 (41.7% vs. 55.3%; P = 0.0016); sr-RD by Week 4/12 significantly reduced SVR24 in patients with scores <5 but not 655. CONCLUSIONS: In conclusion, sr-RD to peginterferon alfa-2a/ribavirin significantly impacts on SVR24 rates in treatment-naive G1 noncirrhotic Caucasian patients. Baseline characteristics can help select patients with a high probability of SVR24 and a low probability of sr-RD with peginterferon alfa-2a/ribavirin

Impact of Safety-Related Dose Reductions or Discontinuations on Sustained Virologic Response in HCV-Infected Patients: Results from the GUARD-C Cohort.

BACKGROUND: Despite the introduction of direct-acting antiviral agents for chronic hepatitis C virus (HCV) infection, peginterferon alfa/ribavirin remains relevant in many resource-constrained settings. The non-randomized GUARD-C cohort investigated baseline predictors of safety-related dose reductions or discontinuations (sr-RD) and their impact on sustained virologic response (SVR) in patients receiving peginterferon alfa/ribavirin in routine practice. METHODS: A total of 3181 HCV-mono-infected treatment-naive patients were assigned to 24 or 48 weeks of peginterferon alfa/ribavirin by their physician. Patients were categorized by time-to-first sr-RD (Week 4/12). Detailed analyses of the impact of sr-RD on SVR24 (HCV RNA <50 IU/mL) were conducted in 951 Caucasian, noncirrhotic genotype (G)1 patients assigned to peginterferon alfa-2a/ribavirin for 48 weeks. The probability of SVR24 was identified by a baseline scoring system (range: 0-9 points) on which scores of 5 to 9 and <5 represent high and low probability of SVR24, respectively. RESULTS: SVR24 rates were 46.1% (754/1634), 77.1% (279/362), 68.0% (514/756), and 51.3% (203/396), respectively, in G1, 2, 3, and 4 patients. Overall, 16.9% and 21.8% patients experienced ≥1 sr-RD for peginterferon alfa and ribavirin, respectively. Among Caucasian noncirrhotic G1 patients: female sex, lower body mass index, pre-existing cardiovascular/pulmonary disease, and low hematological indices were prognostic factors of sr-RD; SVR24 was lower in patients with ≥1 vs. no sr-RD by Week 4 (37.9% vs. 54.4%; P = 0.0046) and Week 12 (41.7% vs. 55.3%; P = 0.0016); sr-RD by Week 4/12 significantly reduced SVR24 in patients with scores <5 but not ≥5. CONCLUSIONS: In conclusion, sr-RD to peginterferon alfa-2a/ribavirin significantly impacts on SVR24 rates in treatment-naive G1 noncirrhotic Caucasian patients. Baseline characteristics can help select patients with a high probability of SVR24 and a low probability of sr-RD with peginterferon alfa-2a/ribavirin.This study was sponsored by F. Hoffmann-La Roche Ltd, Basel, Switzerland. Support for third-party writing assistance for this manuscript, furnished by Blair Jarvis MSc, ELS, of Health Interactions, was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland

Impact of safety-related dose reductions or discontinuations on sustained virologic response in HCV-infected patients: Results from the GUARD-C Cohort

Background: Despite the introduction of direct-acting antiviral agents for chronic hepatitis C virus (HCV) infection, peginterferon alfa/ribavirin remains relevant in many resource-constrained settings. The non-randomized GUARD-C cohort investigated baseline predictors of safety-related dose reductions or discontinuations (sr-RD) and their impact on sustained virologic response (SVR) in patients receiving peginterferon alfa/ribavirin in routine practice. Methods: A total of 3181 HCV-mono-infected treatment-naive patients were assigned to 24 or 48 weeks of peginterferon alfa/ribavirin by their physician. Patients were categorized by time-to-first sr-RD (Week 4/12). Detailed analyses of the impact of sr-RD on SVR24 (HCV RNA <50 IU/mL) were conducted in 951 Caucasian, noncirrhotic genotype (G)1 patients assigned to peginterferon alfa-2a/ribavirin for 48 weeks. The probability of SVR24 was identified by a baseline scoring system (range: 0-9 points) on which scores of 5 to 9 and <5 represent high and low probability of SVR24, respectively. Results: SVR24 rates were 46.1 % (754/1634), 77.1% (279/362), 68.0% (514/756), and 51.3% (203/396), respectively, in G1,2, 3, and 4 patients. Overall, 16.9% and 21.8% patients experienced 651 sr-RD for peginterferon alfa and ribavirin, respectively. Among Caucasian noncirrhotic G1 patients: female sex, lower body mass index, pre-existing cardiovascular/pulmonary disease, and low hematological indices were prognostic factors of sr-RD; SVR24 was lower in patients with 651 vs. no sr-RD by Week 4 (37.9% vs. 54.4%; P = 0.0046) and Week 12 (41.7% vs. 55.3%; P = 0.0016); sr-RD by Week 4/12 significantly reduced SVR24 in patients with scores <5 but not 655. Conclusions: In conclusion, sr-RD to peginterferon alfa-2a/ribavirin significantly impacts on SVR24 rates in treatment-naive G1 noncirrhotic Caucasian patients. Baseline characteristics can help select patients with a high probability of SVR24 and a low probability of sr-RD with peginter-feron alfa-2a/ribavirin

Control of liver abscesses in lambs by using marbofloxacin

We describe cases of liver abscesses in a group of newborn lambs. Diagnosis was based on the combination of clinical signs with the findings of ultrasonographic examination of the abdomen: oval, hypoechoic structure with regular borders in the liver of the affected lambs. Administration of marbofloxacin (dose rate: 3.0 mg per kg bodyweight, on three occasions, once daily, two days apart) was effective for treatment; three weeks later, the affected lambs were clinically health

Copper-based metalwork in Roman to early Islamic Jerash (Jordan): Insights into production and recycling through alloy compositions and lead isotopes

Metallographic, chemical and lead isotopic analyses of copper-based artefacts recovered from the Northwest Quarter in Jerash (ancient Gerasa) in Jordan provide new information on the civic life and material culture from a key urban site in the Roman Empire's eastern provinces. The samples span the city's occupation from its flourishing under Roman rule into the Byzantine and early Islamic periods. We examined 49 copper-based artefacts were examined using reflected light microscopy and micro-X-ray fluorescence. A subset of these artefacts was analysed by electron microprobe spectroscopy for major and minor elements at higher spatial resolution, and by multicollector inductively coupled plasma mass spectrometry for lead isotopes. Results imply that binary bronze dominated the Roman period, (leaded) brass characterised the Byzantine period, while tin-containing alloys were prevalent during the Islamic period. Lead isotopes suggest that during the Roman and Byzantine periods some of the metal in Jerash came from European and/or Mediterranean sources, while copper used during the Islamic period may have been sourced more locally from Timna. The changes in alloy types and lead isotopes suggest that recycling of metals took place in Jerash possibly as early as the Roman period and more frequent from the Byzantine period onwards

Proposals for withdrawal period of sheep milk for some commonly used veterinary medicinal products: A review

This paper summarises the results of studies performed in Greece, in order to establish withdrawal time of sheep milk for some commonly used antimicrobial drugs. Several studies have been performed to establish milk withdrawal time for the following veterinary medicinal products, commonly used in the therapeutics of sheep: lincomycin, spectinomycin, procaine penicillin G,dihydrostreptomycin, kanamycin,oxytetracycline, trimethoprim and sulfadiazine, albendazole. For oxytetracycline, two pharmaceutical forms were tested, specifically long-acting injectable solution and spray. For albendazole, the pharmaceutical form of oral suspension was tested. For all the other antimicrobials, the pharmaceutical form of injectable solution was tested. The animal phase of all the trials was performed at the Veterinary Faculty of the University of Thessaly. Each product was administered at the highest recommended dose and the frequency currently licensed for administration to sheep. Subsequently, either liquid chromatography or liquid chromatography-mass spectrophotometry was used under GLP principles and as required each time, in order to establish residues of each antibiotic in milk. Most of the analytical work was carried out at GLP accredited laboratories. In each case, limit of detection and limit of quantification for each antibiotic tested were appropriately calculated. For calculation and proposal of a withdrawal period, the legally established minimum residue levels of each antibiotic and their concentrations detected in sheep milk were taken into account. The proposed withdrawal periods are as follows: lincomycin and spectinomycin inj. sol.: 4 milkings, procaine penicillin G and dihydrostreptomycin inj. sol.: 5 milkings, dihydrostreptomycin inj. sol.: 5 milkings, kanamycin inj. sol.: 4 milkings, oxytetracycline long-acting inj. sol.: 16 milkings, oxytetracycline spray: 0 milkings, trimethoprim and sulfadiazine inj. sol.: 7 milkings, albendazole or. susp.: 7 milkings after last administration of each test product. The above results provide standards and will help veterinarians to use the various veterinary pharmaceutical products in the therapeutics of dairy ewes. (C) 2009 Elsevier B.V. All rights reserved